WO2002062368A3 - Method of inducing a ctl response - Google Patents
Method of inducing a ctl response Download PDFInfo
- Publication number
- WO2002062368A3 WO2002062368A3 PCT/US2002/002033 US0202033W WO02062368A3 WO 2002062368 A3 WO2002062368 A3 WO 2002062368A3 US 0202033 W US0202033 W US 0202033W WO 02062368 A3 WO02062368 A3 WO 02062368A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- ctl response
- inducing
- mammal
- disclosed
- Prior art date
Links
- 230000001939 inductive effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 241000124008 Mammalia Species 0.000 abstract 3
- 230000001900 immune effect Effects 0.000 abstract 3
- 210000004324 lymphatic system Anatomy 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002247023A AU2002247023A1 (en) | 2001-02-02 | 2002-01-22 | Method of inducing a ctl response |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/776,232 | 2001-02-02 | ||
US09/776,232 US6977074B2 (en) | 1997-07-10 | 2001-02-02 | Method of inducing a CTL response |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2002062368A2 WO2002062368A2 (en) | 2002-08-15 |
WO2002062368A3 true WO2002062368A3 (en) | 2003-09-25 |
WO2002062368A8 WO2002062368A8 (en) | 2003-11-20 |
Family
ID=25106827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/002033 WO2002062368A2 (en) | 2001-02-02 | 2002-01-22 | Method of inducing a ctl response |
Country Status (3)
Country | Link |
---|---|
US (4) | US6977074B2 (en) |
AU (2) | AU784923B2 (en) |
WO (1) | WO2002062368A2 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
NZ337054A (en) * | 1997-01-30 | 2001-03-30 | Chiron Corp | Microparticles PLA and PLG with adsorbed viral antigen to stimulate immune responses particularly for intracellular viruses such as HSV-1 or HSV-2, varicella zoster virus. epstein-barr virus or cytomegalovirus (CMV) |
US20040202680A1 (en) * | 1997-01-30 | 2004-10-14 | O'hagan Derek | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US7279462B1 (en) * | 1998-04-27 | 2007-10-09 | Nevagen Llc | Somatic transgene immunization and related methods |
US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
AU3755800A (en) * | 1999-03-15 | 2000-10-04 | Introgen Therapeutics, Inc. | Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
JP5000807B2 (en) * | 1999-04-27 | 2012-08-15 | ネバジェン エルエルシー | Somatic cell transgene immunization and related methods |
EP1808180A3 (en) | 1999-10-22 | 2010-12-22 | Sanofi Pasteur Limited | Modified GP 100 and uses thereof |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
AU2001258102B2 (en) * | 2000-05-10 | 2007-03-01 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
JP2005505242A (en) * | 2001-03-07 | 2005-02-24 | マンカインド コーポレイション | Anti-neovascular preparation for cancer |
US20050215472A1 (en) | 2001-10-23 | 2005-09-29 | Psma Development Company, Llc | PSMA formulations and uses thereof |
WO2003034903A2 (en) | 2001-10-23 | 2003-05-01 | Psma Development Company, L.L.C. | Psma antibodies and protein multimers |
GB0203276D0 (en) * | 2002-02-12 | 2002-03-27 | Novartis Ag | Organic compounds |
US20030206916A1 (en) * | 2002-05-03 | 2003-11-06 | Rush-Presbyterian-St. Luke's Medical Center | Immunogenic peptides |
DE10225144A1 (en) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding to MHC molecules |
WO2004037284A1 (en) * | 2002-10-22 | 2004-05-06 | Sanofi Pasteur Limited | Anti-cancer vaccines and high-dose cytokines as adjuvants |
US7178491B2 (en) * | 2003-06-05 | 2007-02-20 | Caterpillar Inc | Control system and method for engine valve actuator |
CA2529048A1 (en) * | 2003-06-13 | 2005-02-24 | Becton, Dickinson And Company | Improved intra-dermal delivery of biologically active agents |
WO2004112825A2 (en) * | 2003-06-17 | 2004-12-29 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
EP2356999A1 (en) | 2003-06-17 | 2011-08-17 | Mannkind Corporation | Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
PL202927B1 (en) * | 2003-07-20 | 2009-08-31 | Carr Daniel R | Peptide and pharmaceutical composition as well as their therapeutic applications |
CA2536669A1 (en) * | 2003-08-26 | 2005-03-17 | Becton, Dickinson And Company | Methods for intradermal delivery of therapeutics agents |
JP4976853B2 (en) * | 2003-11-21 | 2012-07-18 | インスティチュート・パスツール | Bordetella's recombinant adenylate cyclase toxin induces a T cell response to tumor antigens |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
US20060008468A1 (en) * | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
WO2006009919A2 (en) * | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
AU2005265182B2 (en) * | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
US8425323B2 (en) * | 2004-06-30 | 2013-04-23 | Wms Gaming Inc. | Wagering game with asset trading |
CA2592922A1 (en) | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
AU2005321905A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass CD+4 cells in the induction of an immune response |
PL1833506T3 (en) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
US20060165711A1 (en) * | 2004-12-29 | 2006-07-27 | Bot Adrian I | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
ES2413079T3 (en) | 2005-06-17 | 2013-07-15 | Mannkind Corporation | Methods and compositions for triggering multivalent immune responses against dominant and subdominant epitopes expressed in cancer cells and tumor stroma |
EP1896498B1 (en) * | 2005-06-17 | 2014-12-24 | MannKind Corporation | Epitope analogues |
US8084592B2 (en) | 2005-06-17 | 2011-12-27 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
EP1945247A1 (en) | 2005-10-18 | 2008-07-23 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
US9005944B2 (en) | 2005-12-14 | 2015-04-14 | The Invention Science Fund I, Llc | Bone cell delivery device |
US8198080B2 (en) | 2005-12-14 | 2012-06-12 | The Invention Science Fund I, Llc | Bone delivery device |
US20110172826A1 (en) * | 2005-12-14 | 2011-07-14 | Amodei Dario G | Device including altered microorganisms, and methods and systems of use |
JP2009531324A (en) | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Engineered anti-prostatic stem cell antigen (PSCA) antibody for cancer targeting |
EP2010530A2 (en) * | 2006-03-23 | 2009-01-07 | Novartis AG | Methods for the preparation of imidazole-containing compounds |
WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
CA2646891A1 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
US20080014211A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
US20080095798A1 (en) * | 2006-10-18 | 2008-04-24 | Robert Humphreys | Ii-key enhanced vaccine potency |
JP5102847B2 (en) * | 2007-02-01 | 2012-12-19 | アバントール パフォーマンス マテリアルズ, インコーポレイテッド | Chromatographic media and chromatographic equipment storage solutions and their use |
CN103736086A (en) | 2007-02-15 | 2014-04-23 | 曼康公司 | A method for enhancing t cell response |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US20090131355A1 (en) * | 2007-05-23 | 2009-05-21 | Adrian Ion Bot | Multicistronic vectors and methods for their design |
WO2009032949A2 (en) | 2007-09-04 | 2009-03-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
JP5731198B2 (en) | 2007-09-27 | 2015-06-10 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | Use of liposomes in carriers containing a continuous hydrophobic phase for delivery of polynucleotides in vivo |
EP3714906A1 (en) * | 2007-10-03 | 2020-09-30 | Cornell University | Treatment of proliferative disorders using radiolabelled antibodies to psma |
CN110075113A (en) | 2008-04-17 | 2019-08-02 | Pds生物科技公司 | Immune response is stimulated by the enantiomer of cation lipid |
EP2296696B1 (en) | 2008-06-05 | 2014-08-27 | ImmunoVaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
US8156070B2 (en) * | 2008-09-05 | 2012-04-10 | Roche Diagnostics Operations, Inc. | Insulin pump programming software with basal profile preview feature |
US8585505B2 (en) | 2008-12-15 | 2013-11-19 | Tetris Online, Inc. | Inter-game interactive hybrid asynchronous computer game infrastructure |
WO2010096486A1 (en) | 2009-02-17 | 2010-08-26 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
RU2673908C2 (en) | 2009-12-02 | 2018-12-03 | Имэджинэб, Инк. | J591 minibodies and cys-diabodies for targeted delivery of human prostate specific membrane antigen (psma) and methods for their use |
CN113876945A (en) | 2011-10-06 | 2022-01-04 | 免疫疫苗技术有限公司 | Liposome composition comprising adjuvant for activating or increasing TLR2 activity and application thereof |
US9149508B1 (en) * | 2011-10-26 | 2015-10-06 | Sigmovir Biosystems, Inc. | Vaccination by circumventing preexistent immunity |
EP2897639A4 (en) | 2012-09-21 | 2016-05-04 | Frank Bedu-Addo | Improved vaccine compositions and methods of use |
WO2014143781A1 (en) | 2013-03-15 | 2014-09-18 | Camas Incorporated | Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities |
KR102132697B1 (en) | 2013-12-05 | 2020-07-10 | 엘지디스플레이 주식회사 | Curved Display Device |
US10816554B2 (en) | 2014-04-04 | 2020-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for T cell receptors |
US20150343139A1 (en) * | 2014-05-30 | 2015-12-03 | Boston Scientific Scimed, Inc. | Implantable pumps and related methods of use |
SG10201912485PA (en) | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
AU2016304764C1 (en) | 2015-08-07 | 2023-06-01 | Imaginab, Inc. | Antigen binding constructs to target molecules |
AU2016354590B2 (en) | 2015-11-13 | 2023-11-23 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
US11472856B2 (en) | 2016-06-13 | 2022-10-18 | Torque Therapeutics, Inc. | Methods and compositions for promoting immune cell function |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
CN111432836A (en) | 2017-09-05 | 2020-07-17 | 转矩医疗股份有限公司 | Therapeutic protein compositions and methods of making and using same |
MA52363A (en) | 2018-04-26 | 2021-03-03 | Agenus Inc | THERMAL SHOCK PROTEIN (HSP) PEPTIDIC COMPOSITIONS AND THEIR METHODS OF USE |
EP3937976A4 (en) * | 2019-03-12 | 2023-03-29 | The General Hospital Corporation | Highly networked immunogen composition |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002183A2 (en) * | 1997-07-10 | 1999-01-21 | Ctl Immunotherapies Corporation | A method of inducing a ctl response |
Family Cites Families (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3604417A (en) * | 1970-03-31 | 1971-09-14 | Wayne Henry Linkenheimer | Osmotic fluid reservoir for osmotically activated long-term continuous injector device |
US3760805A (en) * | 1971-01-13 | 1973-09-25 | Alza Corp | Osmotic dispenser with collapsible supply container |
US3760804A (en) * | 1971-01-13 | 1973-09-25 | Alza Corp | Improved osmotic dispenser employing magnesium sulphate and magnesium chloride |
US4034756A (en) * | 1971-01-13 | 1977-07-12 | Alza Corporation | Osmotically driven fluid dispenser |
US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3732865A (en) * | 1971-01-13 | 1973-05-15 | Alza Corp | Osmotic dispenser |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3929132A (en) * | 1973-04-10 | 1975-12-30 | Alza Corp | Osmotic dispenser |
US3995632A (en) * | 1973-05-04 | 1976-12-07 | Alza Corporation | Osmotic dispenser |
US3987790A (en) * | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
US4203440A (en) * | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4286067A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Article of manufacture comprising semipermeable polymer and dextran derivative |
US4304232A (en) * | 1979-03-14 | 1981-12-08 | Alza Corporation | Unit system having multiplicity of means for dispensing useful agent |
US4450198A (en) * | 1980-01-28 | 1984-05-22 | Alza Corporation | Microporous film with polymer in pores for regulating passage of fluid |
US4439199A (en) * | 1980-02-19 | 1984-03-27 | Alza Corporation | Method for administering immunopotentiator |
US4455142A (en) | 1980-07-07 | 1984-06-19 | Alza Corporation | Method of coadministering an antigen and an immunopotentiator |
US4300558A (en) * | 1980-07-18 | 1981-11-17 | Alza Corporation | Self-driven fluid dispenser |
US4350271A (en) * | 1980-08-22 | 1982-09-21 | Alza Corporation | Water absorbing fluid dispenser |
US4367741A (en) * | 1980-12-22 | 1983-01-11 | Alza Corporation | Dispenser powered by cross-linked hydrophilic polymer grafted to hydrophilic polymer |
US4340054A (en) * | 1980-12-29 | 1982-07-20 | Alza Corporation | Dispenser for delivering fluids and solids |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4340048A (en) * | 1981-03-28 | 1982-07-20 | Alza Corporation | Self-driven hypodermic injector |
US4455145A (en) * | 1981-07-10 | 1984-06-19 | Alza Corporation | Dispensing device with internal drive |
IT1142930B (en) * | 1981-11-04 | 1986-10-15 | Luigi Bernardi | PORTABLE APPARATUS THAT INFUSES INSULIN ON THE BASIS OF GLYCEMIC DETECTION |
US4474575A (en) * | 1982-02-01 | 1984-10-02 | Alza Corporation | Self-driven pump assembly and method of operation |
US4435173A (en) * | 1982-03-05 | 1984-03-06 | Delta Medical Industries | Variable rate syringe pump for insulin delivery |
US4778879A (en) | 1982-04-20 | 1988-10-18 | Sloan-Kettering Institute For Cancer Research | Highly purified human interleukin 2 and method |
US4498843A (en) * | 1982-08-02 | 1985-02-12 | Schneider Philip H | Insulin infusion pump |
US4753651A (en) * | 1982-08-30 | 1988-06-28 | Alza Corporation | Self-driven pump |
US4619652A (en) * | 1982-12-23 | 1986-10-28 | Alza Corporation | Dosage form for use in a body mounted pump |
US4561856A (en) * | 1983-08-18 | 1985-12-31 | Cochran Ulrich D | Infusion pump |
US4552651A (en) * | 1983-11-14 | 1985-11-12 | Conoco Inc. | Control of froth cell performance through the use of differential bubbler tubes |
US4855238A (en) | 1983-12-16 | 1989-08-08 | Genentech, Inc. | Recombinant gamma interferons having enhanced stability and methods therefor |
US4908433A (en) * | 1984-04-25 | 1990-03-13 | Sloan-Kettering Institute For Cancer Research | Uses of interleukin-2 |
NL8403937A (en) * | 1984-12-24 | 1986-07-16 | Cornelis Smit | DEVICE FOR DELIVERING A NUMBER OF LIQUID DOSES. |
DE3937412A1 (en) | 1989-11-10 | 1991-05-16 | Hoechst Ag | SYNTHETIC VACCINE FOR THE SPECIFIC INDUCTION OF CYTOTOXIC T-LYMPHOZYTES |
US4963141A (en) * | 1985-08-16 | 1990-10-16 | Alza Corporation | Dispensing system for administering beneficial agent formulation to ruminants |
US4865598A (en) * | 1985-08-16 | 1989-09-12 | Alza Corporation | Dispensing system for administering beneficial agent |
US4865845A (en) * | 1986-03-21 | 1989-09-12 | Alza Corporation | Release rate adjustment of osmotic or diffusional delivery devices |
US5019384A (en) * | 1986-06-30 | 1991-05-28 | Massachusetts Institute Of Technology | Immunonodulating compositions and their use |
US4838862A (en) * | 1986-08-04 | 1989-06-13 | Pharmetrix Corp. | Portable controlled release osmotic infusion device |
DE3700119A1 (en) | 1987-01-03 | 1988-07-14 | Inst Diabetestechnologie Gemei | IMPLANTABLE ELECTROCHEMICAL SENSOR |
US5110597A (en) * | 1987-06-25 | 1992-05-05 | Alza Corporation | Multi-unit delivery system |
US5023088A (en) * | 1987-06-25 | 1991-06-11 | Alza Corporation | Multi-unit delivery system |
GB2211132B (en) * | 1987-10-22 | 1991-08-14 | Gore & Ass | Bagpipes and a pipe bag therefor |
US4872873A (en) * | 1987-12-14 | 1989-10-10 | Merck & Co., Inc. | Controlled release bolus device |
US4855141A (en) * | 1988-03-25 | 1989-08-08 | Alza Corporation | Device comprising means for protecting and dispensing fluid sensitive medicament |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US4898582A (en) * | 1988-08-09 | 1990-02-06 | Pharmetrix Corporation | Portable infusion device assembly |
US4929233A (en) * | 1988-08-26 | 1990-05-29 | Alza Corporation | Implantable fluid imbibing pump with improved closure |
US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
US5174999A (en) * | 1988-12-13 | 1992-12-29 | Alza Corporation | Delivery system comprising fluid ingress and drug egress |
US5059423A (en) * | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
US5135523A (en) * | 1988-12-13 | 1992-08-04 | Alza Corporation | Delivery system for administering agent to ruminants and swine |
US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
US5110596A (en) | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
US5037420A (en) * | 1988-12-13 | 1991-08-06 | Alza Corporation | Delivery system comprising two sections for delivering somatotropin |
US4976966A (en) * | 1988-12-29 | 1990-12-11 | Alza Corporation | Delayed release osmotically driven fluid dispenser |
PL159857B1 (en) | 1989-01-20 | 1993-01-29 | Method for the continuous control of the carried infusion microbatcher | |
US4929141A (en) * | 1989-02-21 | 1990-05-29 | International Baler Corp. | Bale-opening method and apparatus |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6214804B1 (en) | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
US5328470A (en) * | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5110598A (en) * | 1989-06-30 | 1992-05-05 | Smithkline Beecham Corp. | Intermittent release dosage form |
US5030216A (en) * | 1989-12-15 | 1991-07-09 | Alza Corporation | Osmotically driven syringe |
US5135498A (en) * | 1990-04-02 | 1992-08-04 | Kam Robert J | Controlled release infusion device |
US5017381A (en) * | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
US5257987A (en) * | 1990-05-21 | 1993-11-02 | Pharmetrix Corporation | Controlled release osmotic infusion system |
US5169390A (en) * | 1990-05-21 | 1992-12-08 | Athayde Amulya L | Osmotic infusion device |
EP0533816B1 (en) * | 1990-06-15 | 1995-06-14 | Cortrak Medical, Inc. | Drug delivery apparatus |
US5766601A (en) * | 1990-08-08 | 1998-06-16 | University Of Massachusetts Medical Center | Cross-reactive influenza a immunization |
US5830452A (en) * | 1990-11-20 | 1998-11-03 | Chiron Corporation | Method for enhancing the anti-tumor therapeutic index of interleukin-2 |
GB9027422D0 (en) * | 1990-12-18 | 1991-02-06 | Scras | Osmotically driven infusion device |
DE4143467C2 (en) * | 1991-05-17 | 1995-02-09 | Max Planck Gesellschaft | Peptide motif and its use |
US5137727A (en) | 1991-06-12 | 1992-08-11 | Alza Corporation | Delivery device providing beneficial agent stability |
US5451504A (en) | 1991-07-29 | 1995-09-19 | Serex, Inc. | Method and device for detecting the presence of analyte in a sample |
US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
US5304165A (en) * | 1991-12-09 | 1994-04-19 | Habley Medical Technology Corporation | Syringe-filling medication dispenser |
US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
US6037135A (en) * | 1992-08-07 | 2000-03-14 | Epimmune Inc. | Methods for making HLA binding peptides and their uses |
US5209746A (en) * | 1992-02-18 | 1993-05-11 | Alza Corporation | Osmotically driven delivery devices with pulsatile effect |
US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
DE4238416A1 (en) | 1992-11-13 | 1994-05-19 | Max Planck Gesellschaft | Determination of peptide motifs on MHC molecules |
US5744316A (en) * | 1992-12-22 | 1998-04-28 | Ludwig Institute For Cancer Research | Isolated, tyrosinase derived peptides and uses thereof |
US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
DE69433723T3 (en) * | 1993-02-22 | 2008-10-30 | Abraxis Bioscience, Inc., Los Angeles | PROCESS FOR IN VIVO ADMINISTRATION OF BIOLOGICAL SUBSTANCES AND COMPOSITIONS USED THEREFROM |
ATE386800T1 (en) * | 1993-03-17 | 2008-03-15 | Us Gov Health & Human Serv | IMMUNOGENIC CHIMERAS COMPRISING NUCLEIC ACID SEQUENCES ENCODING ENDOPLASMATIC RETICULUM SIGNAL SEQUENCE PEPTIDES AND AT LEAST ONE OTHER PEPTIDE, THEIR USE IN VACCINES AND FOR THE TREATMENT OF DISEASES |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US5409710A (en) * | 1993-04-20 | 1995-04-25 | Endocon, Inc. | Foam cell drug delivery |
US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US5368562A (en) * | 1993-07-30 | 1994-11-29 | Pharmacia Deltec, Inc. | Systems and methods for operating ambulatory medical devices such as drug delivery devices |
US5595871A (en) * | 1993-08-25 | 1997-01-21 | University Of Scranton | Detection and prevention of mycoplasma hominis infection |
US5679647A (en) * | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
DK0686030T3 (en) | 1993-12-23 | 2001-06-25 | Rmf Dictagene Sa | Microparticles loaded with antigen and pharmaceutical compositions containing these microparticles |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
US5550214A (en) * | 1994-02-10 | 1996-08-27 | Brigham And Women's Hospital | Isolated antigenic oncogene peptide fragments and uses |
US5478556A (en) * | 1994-02-28 | 1995-12-26 | Elliott; Robert L. | Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor |
US5496360A (en) * | 1994-04-12 | 1996-03-05 | Ventritex, Inc. | Implantable cardiac electrode with rate controlled drug delivery |
DE4423392A1 (en) | 1994-07-04 | 1996-01-11 | Birsner & Grob Biotech Gmbh | Methods of identifying antigenic peptides |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
WO1996027008A2 (en) | 1995-02-28 | 1996-09-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., Berlin | Agent for treating tumours and other hyperplasia |
US5962428A (en) * | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5935568A (en) | 1995-05-18 | 1999-08-10 | National Jewish Medical & Research Center | Gene therapy for effector cell regulation |
US5698396A (en) * | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
US5900238A (en) | 1995-07-27 | 1999-05-04 | Immunex Corporation | Vaccine delivery system |
JPH09151200A (en) | 1995-09-29 | 1997-06-10 | Ajinomoto Co Inc | Peptide capable of inducing immune response to human gastric cancer, therapeutic and preventive agent for human gastric cancer containing the same |
US5853719A (en) * | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
CN1203177C (en) | 1996-06-07 | 2005-05-25 | 伊东恭悟 | Tumor antigen proteins, genes thereof and tumor antigen peptides |
US5837231A (en) * | 1996-06-27 | 1998-11-17 | Regents Of The University Of Minnesota | GM-CSF administration for the treatment and prevention of recurrence of brain tumors |
US5951975A (en) | 1996-06-28 | 1999-09-14 | University Of Pittsburgh | Induction of CTLs specific for natural antigens by cross priming immunization |
US5876972A (en) | 1996-09-23 | 1999-03-02 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acid molecules coding for tumor suppressor proteins and methods for their isolation |
US5910306A (en) | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
US6204250B1 (en) * | 1996-11-22 | 2001-03-20 | The Mount Sinai Medical Center Of The City Of New York | Immunization of infants |
ES2158611T3 (en) | 1996-12-20 | 2001-09-01 | Alza Corp | COMPOSITION IN INJECTABLE GEL WITH RETARD EFFECT AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION. |
NZ500018A (en) | 1997-03-31 | 2001-07-27 | Alza Corp | Diffusional implantable delivery system with capillary tube of cross-sectional area and length to deliver beneficial agent |
US6994851B1 (en) * | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
US20030138808A1 (en) * | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
US6861234B1 (en) * | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
US20030215425A1 (en) * | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
JP2003535824A (en) | 2000-04-28 | 2003-12-02 | シーティーエル イムノセラピーズ コーポレーション | Epitope tuning in antigen presenting cells |
JP2005505242A (en) | 2001-03-07 | 2005-02-24 | マンカインド コーポレイション | Anti-neovascular preparation for cancer |
WO2003008537A2 (en) * | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
DE60238864D1 (en) * | 2001-11-07 | 2011-02-17 | Mankind Corp | FOR EPITOPES OF ANTIGENIC ENCODING EXPRESSION VECTORS AND METHOD FOR THEIR DESIGN |
US20040180354A1 (en) * | 2002-09-06 | 2004-09-16 | Simard John J.L. | Epitope sequences |
WO2004112825A2 (en) | 2003-06-17 | 2004-12-29 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
EP2356999A1 (en) | 2003-06-17 | 2011-08-17 | Mannkind Corporation | Compositions to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
WO2006009919A2 (en) | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
US20060008468A1 (en) | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
AU2005265182B2 (en) | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
US20060159689A1 (en) * | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
US7678050B2 (en) * | 2004-08-24 | 2010-03-16 | General Electric Company | Method and apparatus for detecting cardiac events |
CA2592922A1 (en) | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
AU2005321905A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass CD+4 cells in the induction of an immune response |
US20060165711A1 (en) | 2004-12-29 | 2006-07-27 | Bot Adrian I | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes |
PL1833506T3 (en) * | 2004-12-29 | 2016-01-29 | Mannkind Corp | Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines |
US8084592B2 (en) * | 2005-06-17 | 2011-12-27 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
ES2413079T3 (en) * | 2005-06-17 | 2013-07-15 | Mannkind Corporation | Methods and compositions for triggering multivalent immune responses against dominant and subdominant epitopes expressed in cancer cells and tumor stroma |
EP1896498B1 (en) | 2005-06-17 | 2014-12-24 | MannKind Corporation | Epitope analogues |
US20080014211A1 (en) * | 2006-07-14 | 2008-01-17 | Mannkind Corporation | Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic and therapeutic purposes |
CN103736086A (en) | 2007-02-15 | 2014-04-23 | 曼康公司 | A method for enhancing t cell response |
US20090131355A1 (en) | 2007-05-23 | 2009-05-21 | Adrian Ion Bot | Multicistronic vectors and methods for their design |
-
2001
- 2001-02-02 US US09/776,232 patent/US6977074B2/en not_active Expired - Fee Related
- 2001-12-21 AU AU97432/01A patent/AU784923B2/en not_active Ceased
-
2002
- 2002-01-22 WO PCT/US2002/002033 patent/WO2002062368A2/en not_active Application Discontinuation
- 2002-01-22 AU AU2002247023A patent/AU2002247023A1/en not_active Abandoned
-
2005
- 2005-12-19 US US11/313,152 patent/US7364729B2/en not_active Expired - Fee Related
-
2006
- 2006-05-03 US US11/418,497 patent/US20090035252A1/en not_active Abandoned
- 2006-05-03 US US11/418,397 patent/US8372393B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999002183A2 (en) * | 1997-07-10 | 1999-01-21 | Ctl Immunotherapies Corporation | A method of inducing a ctl response |
Non-Patent Citations (3)
Title |
---|
KÜNDIG T ET AL: "On the role of antigen in maintaining cytotoxic T-cell memory", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 93, no. 18, 3 September 1996 (1996-09-03), pages 9716 - 9723, XP002095834, ISSN: 0027-8424 * |
KÜNDIG T M: "[Methods for increasing the immunogenicity of vaccines]", SCHWEIZERISCHE RUNDSCHAU FUR MEDIZIN PRAXIS = REVUE SUISSE DE MEDECINE PRAXIS. SWITZERLAND 14 SEP 2000, vol. 89, no. 37, 14 September 2000 (2000-09-14), pages 1477 - 1484, XP008012660, ISSN: 1013-2058 * |
SCHOTT MATTHIAS ET AL: "Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells.", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 142, no. 3, March 2000 (2000-03-01), pages 300 - 306, XP002228064, ISSN: 0804-4643 * |
Also Published As
Publication number | Publication date |
---|---|
US7364729B2 (en) | 2008-04-29 |
AU784923B2 (en) | 2006-07-27 |
US20120046638A1 (en) | 2012-02-23 |
US6977074B2 (en) | 2005-12-20 |
US8372393B2 (en) | 2013-02-12 |
AU2002247023A1 (en) | 2002-08-19 |
AU9743201A (en) | 2002-08-08 |
WO2002062368A2 (en) | 2002-08-15 |
WO2002062368A8 (en) | 2003-11-20 |
US20090035252A1 (en) | 2009-02-05 |
US20020007173A1 (en) | 2002-01-17 |
US20060153858A1 (en) | 2006-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002062368A8 (en) | Method of inducing a ctl response | |
WO2001021207A3 (en) | Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines | |
WO2002032406A3 (en) | Methods and products related to pulmonary delivery of polysaccharides | |
NZ502168A (en) | Inducing and maintaining a CTL response by delivering antigen to the lymphatic system of a mammal via an external apparatus | |
HK1086750A1 (en) | Pharmaceutical composition for inducing an immune response in a human or animal | |
WO2001034801A3 (en) | Recombinant gelatin in vaccines | |
HK1085652A1 (en) | Stabilized synthetic immunogen delivery system | |
NZ562998A (en) | Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages | |
GB9818627D0 (en) | Improvements in dva vaccination | |
NZ504894A (en) | Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique | |
DE69739253D1 (en) | LIPOSOMAL GRIP VACCINE AND METHOD | |
EP1184370A3 (en) | Compounds with growth hormone releasing properties | |
WO2003080111A3 (en) | Chemotherapeutic agents as anti-cancer vaccine adjuvants and therapeutic methods thereof | |
ATE346606T1 (en) | NERVE GROWTH FACTOR AS A VACCINE ADJUVANT | |
WO2001051008A3 (en) | Selective activation of a th1 or th2 lymphocyte regulated immune response | |
WO2005122739A3 (en) | Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus | |
AU6721801A (en) | The use of plant oil-bodies in vaccine delivery systems | |
ATE78403T1 (en) | VACCINE AGAINST MASTITIS. | |
HK1045209A1 (en) | A vibrator and a method of controlling a vibrator. | |
WO2005028513A3 (en) | High-yield method for the production of human antibodies blocking the biological activity of a human cytokine | |
WO2003011395A3 (en) | Method of utilizing neurotrophins to manipulate reproductive capacity | |
WO2006002195A3 (en) | Method of complexing a protein by the use of a dispersed system and proteins thereof | |
WO2001034185A3 (en) | Induction of mucosal immunity by vaccination via the skin route | |
WO2002032455A3 (en) | Vaccine | |
EP1197889A4 (en) | Schedule communication method, apparatus, and system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 33/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION Free format text: IN PCT GAZETTE 33/2002 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |